The
design, synthesis, and biological evaluation of irciniastatin
A (1) analogues, achieved by removal of three synthetically
challenging structural units, as well as by functional group manipulation
of the C(11) substituent of both irciniastatins A and B (1 and 2), has been achieved. To this end, we first designed
a convergent synthetic route toward the diminutive analogue (+)-C(8)-desmethoxy-C(11)-deoxy-C(12)-didesmethylirciniastatin (6). Key transformations
include an acid-catalyzed 6-exo-tet pyran cyclization,
a chiral Lewis acid mediated aldol reaction, and a facile amide union.
The absolute configuration of 6 was confirmed via spectroscopic
analysis (CD spectrum, HSQC, COSY, and ROESY NMR experiments). Structure–activity
relationship (SAR) studies of 6 demonstrate that the
absence of the three native structural units permits access to analogues
possessing cytotoxic activity in the nanomolar range. Second, manipulation
of the C(11) position, employing late-stage synthetic intermediates
from our irciniastatin syntheses, provides an additional five analogues
(7–11). Biological evaluation of
these analogues indicates a high functional group tolerance at position
C(11).